Synthetic Platelets for Targeted Hemostasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating vascular injuries and conditions, such as allogenic platelet transfusions and recombinant coagulation factors, are limited by short shelf life, immunogenicity, thromboembolic complications, and toxicity, making them ineffective in controlling uncontrolled bleeding in severe trauma.
Innovation Solution
Development of synthetic platelets comprising biocompatible flexible nanoparticles with site-targeted peptides and a therapeutic agent, which adhere to specific vascular sites and deliver therapeutic agents via site-relevant enzymes, mimicking natural platelet adhesion and aggregation mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogenic platelet transfusions are used to halt bleeding, then hemostasis is improved, but immunogenicity and transfusion-associated complications increase
Solution Approach 1:
The patent creates synthetic platelets that copy the essential functions of natural platelets without using actual biological platelets. The synthetic particles mimic platelet adhesion, aggregation, and hemostatic functions through engineered surface properties and encapsulated coagulation factors, eliminating immunogenicity while preserving therapeutic effectiveness
Solution Approach 2:
The patent uses synthetic nanoparticle intermediaries that mediate hemostasis through controlled release of coagulation factors and platelet activation signals. These intermediaries replace direct allogenic platelet transfusion, providing the necessary hemostatic function without the harmful immunogenic components
2Reliability
If recombinant coagulation factors are administered to augment hemostasis, then bleeding control is improved, but thromboembolic complications increase
Solution Approach 1:
The patent designs synthetic platelets with localized delivery of coagulation factors directly to the injury site through targeted adhesion mechanisms. The factors are released locally at the vascular injury location rather than systemically, achieving effective hemostasis control while minimizing systemic thromboembolic risks
Solution Approach 2:
The patent segments the hemostatic function into distinct components: adhesion molecules for target recognition, encapsulated coagulation factors for localized delivery, and surface properties for platelet recruitment. This segmentation allows controlled local action without systemic thrombotic effects
3Reliability
If traditional coagulation treatments are used, then bleeding control is achieved, but shelf life and storage stability are limited
Solution Approach 1:
The patent pre-loads synthetic platelets with encapsulated coagulation factors and activates adhesion molecules during manufacturing. The particles are prepared in advance with all necessary hemostatic components intact and stable, enabling long-term storage while maintaining full therapeutic functionality upon administration
Solution Approach 2:
The patent uses lipid-based nanoparticle encapsulation to protect coagulation factors from degradation, changing the physical state and environment of the factors to enhance stability. The synthetic matrix provides a protective microenvironment that extends shelf life while preserving biological activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The synthetic platelets effectively promote hemostasis by adhering to vascular injury sites, aggregating active platelets, and delivering therapeutic agents, thereby enhancing primary and secondary hemostasis and reducing bleeding time in vascular injuries.
Implementation Method 1
The nanoparticle includes an outer surface and a plurality of site targeted peptides conjugated to the surface. The synthetic platelet adheres to the site targeted
Implementation Method 2
The therapeutic agent can be released at the site targeted via a site-relevant enzyme, which cleaves or destabilizes the nanoparticle to release the therapeutic agent
Implementation Method 3
the flexible nanoparticle shape, size and/or elastic modulus upon administration to a vasculature of a subject can facilitate margination to a vascular wall
Data Source
AI summary
A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.